Shots:

• The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (carboplatin and paclitaxel) with/without Avastin (bevacizumab) vs Bevacizumab and CT in 1-202 patients in a ratio (1:1:1) with stage IV recurrent metastatic non-sq NSCLC- no prior treatment with CT
• The P-III IMpower150 study results: OS (19.2 vs 14.7 mos.); no new safety signals are observed
• Tecentriq is a mAb targeting PD-L1 expressing tumor cells when combined with bevacizumab + CT enhances its ability to restore anti-cancer immunity to combat 1L advanced NSCLC

Ref: PRNewswire | Image: Roche